Literature DB >> 3311324

The natural history of multiple sclerosis.

B G Weinshenker1, G C Ebers.   

Abstract

Studies which have attempted to define the outcome of multiple sclerosis (MS) have methodologic difficulties arising from patient referral biases and the length of follow-up required, which make prospective studies of an inception cohort unrealistic. Means to improve the validity of retrospective natural history studies are suggested. Results of existing series are summarized and compared. Survival is only rarely shortened by MS, but disability to the point of requiring aids for ambulation occurs in 30-70% of patients by 15 years from onset of symptoms. Disagreement as to the percentage of patients who are ultimately bedridden by MS likely arises in large part due to differences in patient ascertainment and follow-up. The need to develop early clinical markers for the patient at high risk for rapid development of major disability is stressed.

Entities:  

Mesh:

Year:  1987        PMID: 3311324     DOI: 10.1017/s0317167100026573

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  19 in total

1.  [MS registry in Germany--design and first results of the pilot phase].

Authors:  P Flachenecker; U K Zettl; U Götze; J Haas; S Schimrigk; W Elias; M Pette; M Eulitz; M Hennig; J Bertram; R Hollweck; A Neiss; M Daumer; D Pitschnau-Michel; P Rieckmann
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

Review 2.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

Review 3.  Does a placebo-effect exist in clinical trials on multiple sclerosis? Review of the literature.

Authors:  L La Mantia; M Eoli; A Salmaggi; C Milanese
Journal:  Ital J Neurol Sci       Date:  1996-04

Review 4.  Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.

Authors:  J H Simon
Journal:  West J Med       Date:  1996-06

5.  Multiple Sclerosis and its Management: The multidisciplinary team approach to management.

Authors:  B Weinshenker
Journal:  Can Fam Physician       Date:  1992-09       Impact factor: 3.275

Review 6.  Development and pilot phase of a European MS register.

Authors:  Peter Flachenecker; Laura Khil; Sverrir Bergmann; Mariusz Kowalewski; Ion Pascu; Francisco Pérez-Miralles; Jaume Sastre-Garriga; Thomas Zwingers
Journal:  J Neurol       Date:  2010-05-05       Impact factor: 4.849

Review 7.  Managing advanced multiple sclerosis.

Authors:  R W Teasell
Journal:  Can Fam Physician       Date:  1993-05       Impact factor: 3.275

8.  Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death.

Authors:  Noel G Carlson; Monica A Rojas; Jonathan W Redd; Philip Tang; Blair Wood; Kenneth E Hill; John W Rose
Journal:  J Neuroinflammation       Date:  2010-04-13       Impact factor: 8.322

9.  The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.

Authors:  Antonio Scalfari; Anneke Neuhaus; Alexandra Degenhardt; George P Rice; Paolo A Muraro; Martin Daumer; George C Ebers
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

10.  Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells.

Authors:  Michael Gurevich; Tamir Tuller; Udi Rubinstein; Rotem Or-Bach; Anat Achiron
Journal:  BMC Med Genomics       Date:  2009-07-22       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.